Journal of Neurochemistry

Journal Information
ISSN / EISSN : 0022-3042 / 1471-4159
Published by: Wiley-Blackwell (10.1111)
Total articles ≅ 30,160
Current Coverage
SCOPUS
MEDLINE
PUBMED
MEDICUS
SCIE
Archived in
EBSCO
SHERPA/ROMEO
Filter:

Latest articles in this journal

Kenta Tezuka, Masayoshi Suzuki, Risa Sato, Shohei Kawarada, ,
Published: 22 January 2022
Journal of Neurochemistry; https://doi.org/10.1111/jnc.15578

The publisher has not yet granted permission to display this abstract.
Published: 20 January 2022
Journal of Neurochemistry, Volume 160, pp 145-153; https://doi.org/10.1111/jnc.15386

Published: 20 January 2022
Journal of Neurochemistry, Volume 160, pp 297-304; https://doi.org/10.1111/jnc.15388

, Vasily Aleshin, Isabel Nogues, Thilo Kähne, Alessia Parroni, Roberto Contestabile, Martino Luigi di Salvo, Anastasia Graf, Angela Tramonti
Published: 20 January 2022
Journal of Neurochemistry; https://doi.org/10.1111/jnc.15576

The publisher has not yet granted permission to display this abstract.
Cátia R. Lopes, Inês M. Amaral, Marlene F. Pereira, João P. Lopes, Daniela Madeira, , ,
Published: 19 January 2022
Journal of Neurochemistry; https://doi.org/10.1111/jnc.15575

The publisher has not yet granted permission to display this abstract.
Jinsong Xue, Guangying Li, Xiaowen Ji, Zhi‐Hua Liu, Hui‐Li Wang,
Published: 17 January 2022
Journal of Neurochemistry; https://doi.org/10.1111/jnc.15574

The publisher has not yet granted permission to display this abstract.
, , , Thomas Liepold, Petra Rieper, Hermann Esselmann, , ,
Published: 4 January 2022
Journal of Neurochemistry; https://doi.org/10.1111/jnc.15571

Abstract:
Neurochemical biomarkers can support the diagnosis of Alzheimer’ disease and may facilitate clinical trials. In blood plasma, the ratio of the amyloid-β (Aβ) peptides Aβ−3–40/Aβ1–42 can predict cerebral amyloid-β pathology with high accuracy (Nakamura et al., 2018). Whether or not Aβ−3–40 (aka. amyloid precursor protein (APP) 669-711) is also present in cerebrospinal fluid (CSF) is not clear. Here, we investigated whether Aβ−3–40 can be detected in CSF and to what extent the CSF Aβ−3–40/Aβ42 ratio is able to differentiate between individuals with or without amyloid-β positron emission tomography (PET) evidence of brain amyloid. The occurrence of Aβ−3–40 in human CSF was assessed by immunoprecipitation followed by mass spectrometry. For quantifying the CSF concentrations of Aβ−3–40 in 23 amyloid PET-negative and 17 amyloid PET-positive subjects, we applied a sandwich-type immunoassay. Our findings provide clear evidence of the presence of Aβ−3–40 and Aβ−3–38 in human CSF. While there was no statistically significant difference in the CSF concentration of Aβ−3–40 between the two diagnostic groups, the CSF Aβ−3–40/Aβ42 ratio was increased in the amyloid PET-positive individuals. We conclude that Aβ−3–40 appears to be a regular constituent of CSF and may potentially serve to accentuate the selective decrease of CSF Aβ42 in Alzheimer’s disease.
Eline Pottie,
Published: 3 January 2022
Journal of Neurochemistry; https://doi.org/10.1111/jnc.15570

Abstract:
Serotonergic psychedelics are substances that induce alterations in mood, perception and thought, and have the activation of serotonin (5-HT) 2A receptors (5-HT2ARs) as a main pharmacological mechanism. Besides their appearance on the (illicit) drug market, e.g. as new psychoactive substances, their potential therapeutic application is increasingly explored. This group of substances demonstrates a broad structural variety, leading to insufficiently described structure-activity relationships, hence illustrating the need for better functional characterization. This review therefore elaborates on the in vitro molecular techniques that have been used the most abundantly for the characterization of (psychedelic) 5-HT2AR agonists. More specifically, this review covers assays to monitor the canonical G protein signaling pathway (e.g. measuring G protein recruitment/activation, inositol phosphate accumulation, or Ca2+ mobilization), assays to monitor non-canonical G protein signaling (such as arachidonic acid release), assays to monitor β-arrestin recruitment or signaling, and assays to monitor receptor conformational changes. In particular, focus lies on the mechanism behind the techniques, and the specific advantages and challenges that are associated with these. Additionally, several variables are discussed that one should consider when attempting to compare functional outcomes from different studies, both linked to the specific assay mechanism and linked to its specific execution, as these may heavily impact the assay outcome.
Back to Top Top